NACOP-Trial (Neuralgic Amyotrophy as a cause of Phrenicus-Neuropathy)

NACOP-Trial (Neuralgic Amyotrophy as a cause of Phrenicus-Neuropathy) - NACOP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032586

Enrollment

Registered

2023-08-31

Start date

2023-04-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G54.5

Interventions

Group 1: Incidence of definite or probable Neuralgic Amyotrophy temporally associated with the presence of a unilateral or bilateral phrenic lesion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Diagnosis of unilateral or bilateral diaphragmatic paresis judged to be idiopathic with symptom onset < 12 months prior to study inclusion. - Informed and signed consent

Exclusion criteria

Exclusion criteria: - Progression of pain symptoms or paresis over > 3 months - Exclusively passive limitation of movement in the glenohumeral joint - Horner syndrome - Absolutely symmetrical expression of the paresis - Individuals who are in a dependent or employment relationship with the investigator. - Placement in an institution due to court or official order - Incapacitated patient - Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Prevalence of definite, probable, or possible Neuralgic Amyotrophy in temporal relation to the diagnosis of diaphragmatic paresis judged to be idiopathic.	—

Secondary

Measure	Time frame
- Prevalence of torsions/constrictions detected visually by high-resolution sonography, MR neurography or intraoperatively. visual torsions/constrictions of the phrenic nerve ipsilateral to the Diaphragmatic Paresis - prevalence of pathologic findings on sensory and motor neurography ipsilateral to diaphragmatic paresis - Prevalence of serological evidence of (sub)acute hepatitis E infection - Prevalence of serological detection of anti-ganglioside antibodies - Description of denervation edema after acute damage to the phrenic nerve - Pulmonary functional and respiratory characterization (descriptive).	—

Measure

Time frame

- Prevalence of torsions/constrictions detected visually by high-resolution sonography, MR neurography or intraoperatively. visual torsions/constrictions of the phrenic nerve ipsilateral to the Diaphragmatic Paresis - prevalence of pathologic findings on sensory and motor neurography ipsilateral to diaphragmatic paresis - Prevalence of serological evidence of (sub)acute hepatitis E infection - Prevalence of serological detection of anti-ganglioside antibodies - Description of denervation edema after acute damage to the phrenic nerve - Pulmonary functional and respiratory characterization (descriptive).

—

Countries

Germany

Contacts

Public ContactJohannes Fabian Holle

Klinik für Neurologie und Klinik für Pneumologie - Lungenklinik // Universität Witten-Herdecke - Lehrstuhl für Pneumologie

hollej@kliniken-koeln.de+49221890713621

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026